A5083291076- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Chromatin Remodeling and Cancer
- T-cell and Retrovirus Studies
- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Cytomegalovirus and herpesvirus research
- Hematopoietic Stem Cell Transplantation
- Pharmaceutical studies and practices
- Neutropenia and Cancer Infections
- Acute Myeloid Leukemia Research
- Neuroblastoma Research and Treatments
- Viral-associated cancers and disorders
- Hemoglobinopathies and Related Disorders
- Nuclear Structure and Function
- Cancer-related gene regulation
- PARP inhibition in cancer therapy
- DNA Repair Mechanisms
- Ubiquitin and proteasome pathways
- Mentoring and Academic Development
- Prenatal Screening and Diagnostics
- Pharmacovigilance and Adverse Drug Reactions
- Immune Cell Function and Interaction
- Diversity and Career in Medicine
Joe DiMaggio Children's Hospital
2016-2024
Memorial Regional Hospital
2024
Columbia University
2015
Columbia University Irving Medical Center
2012-2014
NewYork–Presbyterian Hospital
2012-2014
New York Hospital Queens
2012-2014
Morgan Stanley Children's Hospital
2012-2014
Bacterial septicemia remains the leading cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (AlloHCT). While murine studies have found acute gastrointestinal graft-vs-host disease (aG-GVHD) to be associated with increased incidence enteric bacterial bloodstream infections (EB-BSI), this association has not been studied in humans. We hypothesized that patients who developed aG-GVHD, EB-BSI density after onset aG-GVHD would higher than before without GVHD...
The National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial enrolled children aged 1-21 years with treatment-refractory solid tumors and predefined actionable genetic alterations. Patients harboring alterations in DNA damage repair (DDR) genes were assigned to receive olaparib.
Abstract Background Effective networking and mentorship are critical determinants of career satisfaction success in academic medicine. The American Society Pediatric Hematology/Oncology (ASPHO) mentoring program was developed to support Early Career (EC) members. Herein, the authors report on initial 2‐year outcomes this novel program. Procedure Mentees selected mentors with expertise different subspecialties within field from mentor profiles at ASPHO Web site. Of 23 enrolled pairs, 19 16...
Nuclear protein in testis carcinoma is a rare and highly aggressive associated with 70% mortality rate 1 year from diagnosis median survival of only 6.5 months. No established treatment protocol exists, although some success has been achieved using multimodal approach including early surgical resection adjuvant chemotherapy radiation. Prior studies have not demonstrated successful the absence upfront resection. We describe first reported case patient unresectable nuclear treated successfully...
Abstract Post‐transplant lymphoproliferative disorders of T‐cell origin are quite uncommon, and the vast majority represent neoplasms mature, post‐thymic T‐ or natural killer cells. Here, we report a rare case acute lymphoblastic leukaemia (T‐ALL), which occurred in an 18‐year‐old man who had undergone three liver transplants, initially for biliary atresia subsequently graft failure due to chronic rejection. He received immunosuppression with cyclosporine tacrolimus, as well short‐term...
Bacterial septicemia is a leading cause of mortality following AlloHCT. A few studies have reported higher incidence BSI in patients with aGVHD, supporting the theory that aGVHD associated an increased risk infection. The aim our study was to evaluate relationship between presence gut and subsequent development EB-BSI. In this retrospective study, EB-BSI (enterococci gram-negative rods) data collected day 0 +180 AlloHCT, rates were compared before after onset aGVHD. Two hundred sixty four...
Abstract Introduction: Selinexor is a first-in-class, central nervous system (CNS) penetrant, oral inhibitor of exportin 1 (XPO1), the sole nuclear exporter many key tumor suppressors. FDA-approved for refractory multiple myeloma and DLBCL has been evaluated in phase trial children with leukemia. We report selinexor adolescents recurrent CNS solid tumors, including lymphoma (NCT02323880). Methods: A rolling-six design was used to evaluate (10 or 25 mg tablets) administered twice once weekly...